Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Antifibrosis: To reverse the irreversible
Ziv Paz,
Yehuda Shoenfeld
*
*
Corresponding author for this work
Clinical Departments
Sheba Medical Center at Tel Hashomer
Tel Aviv University
Research output
:
Contribution to journal
›
Review article
›
peer-review
32
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antifibrosis: To reverse the irreversible'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Fibrosis
100%
Anti-fibrosis
100%
Molecular Mechanism
33%
Connective Tissue
33%
Clinical Course
33%
Overproduction
33%
Chemokines
33%
Pathological Process
33%
Intravenous Immunoglobulin (IVIg)
33%
Extracellular Matrix
33%
Interferon-α (IFN-α)
33%
Scar Formation
33%
Life-limiting Conditions
33%
Tissue Damage
33%
Multiple Organs
33%
Immunosuppressive Agents
33%
Irreversible Processes
33%
Anti-inflammatory Agents
33%
Cell Cytokines
33%
Relaxin
33%
Fibrotic Diseases
33%
Antifibrotic
33%
Mycophenolate Mofetil
33%
Fibrotic Process
33%
Tissue Enzymes
33%
Medicine and Dentistry
Fibrosis
100%
Disease
66%
Connective Tissue
33%
Immunoglobulin
33%
Chemokine
33%
Interferon
33%
Cytokine
33%
Disease Course
33%
Extracellular Matrix
33%
Tissue Injury
33%
Scar Formation
33%
Immunosuppressive Drug
33%
Pathological Process
33%
Antiinflammatory Agent
33%
Relaxin
33%
Mycophenolic Acid
33%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosis
100%
Disease
66%
Chemokine
33%
Cytokine
33%
Scar Formation
33%
Disease Course
33%
Immunosuppressive Agent
33%
Immunoglobulin
33%
Interferon
33%
Tissue Injury
33%
Antiinflammatory Agent
33%
Relaxin
33%
Mycophenolic Acid
33%